FDA warned Allay Pharmaceuticals over CGMP failures and sub-potent tablets, and distribution of an unapproved biological product.
What happened
FDA inspected Allay's drug manufacturing facility in Hialeah, Florida, from May 5 to 15, 2020. The agency found inadequate process validation and sub-potent tablet samples, incomplete out-of-specification investigations and inappropriate assay specifications, inadequate stability testing, and quality-unit oversight failures. FDA also determined the firm distributes a tablet biological product without FDA approval or a valid biologics license.
What FDA found
The company failed to adequately validate tablet manufacturing, and FDA found sub-potent samples and one content-uniformity failure.
21 CFR 211.100(a)The company did not thoroughly investigate out-of-specification results and set assay specifications looser than the USP standard, missing 13 lots that exceeded its revised specification.
21 CFR 211.192The company's stability program was inadequate because long-term stability data were missing for validation batches using a new API supplier, and disintegration testing was not consistently done.
21 CFR 211.166(a)The quality control unit failed to oversee API supplier qualification, laboratory computer controls, and complaint handling.
21 CFR 211.22The company distributed a (b)(4) tablet biological product without FDA approval or a valid biologics license.
What FDA wants
FDA tells Allay to correct the violations promptly, respond in writing within 15 working days, and provide detailed plans for process validation, investigations, stability, supplier qualification, quality-unit remediation, and testing of lots within expiry. FDA also recommends a qualified CGMP consultant.
Who should pay attention
- companies that contract with Allay to make finished drug products
- product owners and distributors of the affected tablets or biological product
- quality teams overseeing API supplier qualification and stability programs
This is a summary. Read the original letter on fda.gov.